Research Article| Volume 9, ISSUE 4, P422-425, 1987

Immunoglobulin therapy in the West syndrome

      This paper is only available as a PDF. To read, Please Download here.
      An examination was made of high dose non-treated immunoglobulin (NTIG) therapy at an early stage of the West syndrome (WS). Six patients with cryptogenic WS who suffered attacks ranging from 15 days to 6 months (mean 70 days) and 5 patients with symptomatic WS who suffered attacks ranging from 14 days to 4 months (mean 32 days), were administered NTIG 6–10 times intravenously at 100–200 mg/kg of body weight at intervals of 2 or 3 weeks. All patients with cryptogenic WS showed complete remission in accordance with normalized electroencephalogram (EEG) without following anticonvulsants medication. Of the 5 patients with symptomatic WS one patient showed cessation of clinical seizures in agreement with EEG improvement and 2 other patients revealed transient cessation of clinical seizures with recurrence. In cases of complete remission, the energy percentage of the power spectrum for each frequency band displayed a tendency toward gradual decrease of 8 wave band in correspondence with the increase of 6 wave band percentage after NTIG therapy, suggesting that high dose NTIG may be useful for early treatment of cryptogenic WS and for inhibiting brain deterioration owing to epileptic encephalopathy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lombroso CT
        A prospective study of infantile spasms: clinical and therapeutic correlations.
        Epilepsia. 1983; 24: 135-158
        • Péchadre JC
        • Sauvezie B
        • Osier C
        • Gilvert J
        Traitment des Encephalopathies epileptiques de l'enfant par les gammaglobulines.
        Rev EEG Neurophysiol. 1977; 7: 443-447
        • Laffont F
        • Esnault S
        • Gilbert A
        • Peytour MA
        Effect des gammaglobulines sur des epilepsies rebelles.
        Ann Med Interne. 1979; 130: 307-312
        • Ariizumi M
        • Baba K
        • Shiihara H
        • et al.
        High dose gammaglobulin for intractable childhood epilepsy.
        Lancet. 1983; 8342: 162-163
        • Ariizumi M
        • Baba K
        • Ogawa K
        • et al.
        Early treatment of intractable childhood epilepsy with intravenous immunoglobulin.
        Nihon Univ J Med (Tokyo). 1984; 26: 229-242
        • Sandstedt P
        • Kostulas V
        • Lasson LE
        Intravenous gammaglobulin for post-encephalitic epilepsy.
        Lancet. 1984; 8412: 1154-1155
        • Ariizumi M
        • Hibio S
        • Ogawa K
        • Michihiro N
        • Shiihara H
        • Utsumi Y
        Comparative study on non-treated and pepsintreated immunoglobulin therapy for idiopathic Lennox syndrome.
        Brain Dev (Tokyo). 1984; 6: 422-423
        • Aarli JA
        • Apariuio SR
        • Lumusden CE
        • Tönder O
        Binding of normal human IgG for myelin sheaths, glia and neurons.
        Immunology. 1975; 28: 171-185